tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Alveolar Bone Loss D016301 10 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Glycosuria D006029 10 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Fatigue D005221 10 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Vision Disorders D014786 10 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Long QT Syndrome D008133 10 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Dyspnea D004417 10 associated lipids
Hemophilia A D006467 10 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Shock D012769 11 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Thinness D013851 11 associated lipids
Shock, Septic D012772 11 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Dehydration D003681 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Exanthema D005076 11 associated lipids
Hyperpigmentation D017495 11 associated lipids
Influenza, Human D007251 11 associated lipids
Hypertension, Portal D006975 12 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Retinoblastoma D012175 12 associated lipids
Osteoporosis D010024 12 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Listeriosis D008088 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Eye Diseases D005128 12 associated lipids
Crohn Disease D003424 12 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Keloid D007627 12 associated lipids
Hypoglycemia D007003 13 associated lipids
Urticaria D014581 13 associated lipids
Hypercalcemia D006934 13 associated lipids
Biliary Fistula D001658 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Corneal Diseases D003316 13 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Glucose Intolerance D018149 13 associated lipids
Bradycardia D001919 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Rosacea D012393 13 associated lipids
Hematuria D006417 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Critical Illness D016638 13 associated lipids
Sarcoidosis D012507 13 associated lipids
Alopecia D000505 14 associated lipids
Stomatitis D013280 14 associated lipids
Vasculitis D014657 14 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Uveitis D014605 14 associated lipids
Tremor D014202 15 associated lipids
Encephalitis D004660 15 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Testicular Diseases D013733 15 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hemorrhage D006470 15 associated lipids
Neutropenia D009503 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Vascular Diseases D014652 16 associated lipids
Ulcer D014456 16 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Choline Deficiency D002796 16 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Cholelithiasis D002769 16 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Dermatomycoses D003881 17 associated lipids
Brain Infarction D020520 17 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Ischemia D007511 18 associated lipids
Albuminuria D000419 18 associated lipids
Down Syndrome D004314 18 associated lipids
Mycoses D009181 18 associated lipids
Lymphoma D008223 18 associated lipids
Nephritis D009393 19 associated lipids
Hypothermia D007035 19 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Peptic Ulcer D010437 19 associated lipids
Pregnancy Complications D011248 19 associated lipids
Cough D003371 19 associated lipids
Brain Edema D001929 20 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hara Y et al. Unresponsiveness to rat cardiac allografts induced by intrathymic injection of donor bone marrow cells and short course of immunosuppression. 1994 Transplant. Proc. pmid:7527955
Braun F et al. Primary tacrolimus immunosuppression in kidney recipients considered "higher immunological risk". 2000 Transplant. Proc. pmid:11119893
Kamińska D et al. Significant infections after hand transplantation in a Polish population. 2014 Transplant. Proc. pmid:25380943
Tzakis AG et al. Two-year experience with FK 506 in pediatric patients. 1993 Transplant. Proc. pmid:7679822
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin. 1994 Transplant. Proc. pmid:7513476
Ochiai T et al. Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. 1991 Transplant. Proc. pmid:1721255
Pham SM et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. 1996 Transplant. Proc. pmid:8623208
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Marin-Gomez LM et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. 2009 Jul-Aug Transplant. Proc. pmid:19715867
Aktürk S et al. Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough Levels. 2015 Transplant. Proc. pmid:26093738
Shoji T et al. Long-term acceptance of porcine pulmonary allografts without chronic rejection. 2005 Jan-Feb Transplant. Proc. pmid:15808551
Ortiz de Urbina J et al. Advagraf de novo in liver transplantation: a single-center experience. 2011 Transplant. Proc. pmid:21486583
Van Buren D et al. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus). 1998 Transplant. Proc. pmid:9636566
Qu W et al. Correlation Between Immunosuppressive Therapy and CD4(+) T-Cell Intracellular Adenosine Triphosphate Levels in Liver Transplant Recipients. Transplant. Proc. pmid:27569951
Hossain MA et al. Effect of the immunosuppressants FK506 and D-allose on allogenic orthotopic liver transplantation in rats. 2000 Transplant. Proc. pmid:11120048
Mañez R et al. Association between donor-recipient HLA-DR compatibility and cytomegalovirus hepatitis and chronic rejection in liver transplantation. 1993 Transplant. Proc. pmid:7680170
Sekido H et al. Successful conversion from cyclosporine to tacrolimus for immunosuppression. 2000 Transplant. Proc. pmid:11120096
Ali MN et al. Case series: hemolytic uremic syndrome--another cause of transplant dysfunction. 2013 Transplant. Proc. pmid:24182801
Woan MC et al. Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. 1993 Transplant. Proc. pmid:7680171
Müller MK et al. Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. 1991 Transplant. Proc. pmid:1721286
Friemann S et al. Conversion to tacrolimus in hyperlipidemic patients. 1999 Transplant. Proc. pmid:10576042
Francavilla A et al. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. 1991 Transplant. Proc. pmid:1721287
Carobbi A et al. Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. 1992 Transplant. Proc. pmid:1373543
Ketel BL et al. Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation. 1996 Transplant. Proc. pmid:8623453
Kyo M et al. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin. 1996 Transplant. Proc. pmid:8623457
Batista F et al. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation. 2012 Transplant. Proc. pmid:23146461
Yasunami Y et al. Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. 1990 Transplant. Proc. pmid:1691557
Hu RH et al. Effects of and predictors for tacrolimus rescue therapy among renal transplant patients under cyclosporine-based immunosuppression. 2004 Transplant. Proc. pmid:15518757
Kawaoka T et al. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. 2015 Transplant. Proc. pmid:25891736
Peddi VR et al. Long-term kidney and pancreas function with tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation. 1998 Transplant. Proc. pmid:9636626
Mueller AR et al. Association between hepatitis and rejection: upregulation of cytokines and extracellular matrix parameters. 1997 Transplant. Proc. pmid:9365585
Deardon DJ et al. Small bowel tonometry: a possible technique for detecting early small bowel allograft dysfunction. 1993 Transplant. Proc. pmid:7505502
Curro G et al. Transient ischemic attack after rizatriptan administration in a liver transplant recipient: a case report. 2006 Transplant. Proc. pmid:17112920
Ohtsuka S et al. Mechanism of antibody production in guinea pig to rat discordant xenotransplant: establishment of a simple model by intravenous injection of discordant splenocytes. 1994 Transplant. Proc. pmid:7518130
Uchida H et al. Experimental intestinal transplantation using mouse fetal intestine in the rat: combination effect of FK 506 with cyclophosphamide. 1999 Transplant. Proc. pmid:10578297
Manu MA et al. Tacrolimus rescue for resistant rejection, chronic rejection, and immunoglobulin A nephropathy of renal allografts under primary cyclosporine A immunosuppression. 1999 Transplant. Proc. pmid:10578313
Woodle ES et al. FK 506 rescue therapy: early conversion improves efficacy. 1993 Transplant. Proc. pmid:7682359
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Yagihashi A et al. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721318
Jacob DA et al. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. 2005 Transplant. Proc. pmid:15919432
Wasilewski G et al. Inadequate blood pressure control in orthotopic heart transplant: is there a role of kidney function and immunosuppressive regimen? 2014 Transplant. Proc. pmid:25380929
Ciancio G et al. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center. Transplant. Proc. pmid:27569936
Jin KB et al. The production of reactive oxygen species in tacrolimus-treated glial cells. 2008 Transplant. Proc. pmid:18929834
Tanabe K et al. Synergistic effect of high-dose mizoribine and low-dose tacrolimus on renal allograft survival in nonhuman primates. 2002 Transplant. Proc. pmid:12176425
Chuang JP et al. Does immunosuppressive pharmacotherapy affect isoagglutinin titers? 2008 Transplant. Proc. pmid:18929836
Ito Y et al. Inhibition of epithelial replacement by nonspecific immunosuppressants accelerates rat orthotopic tracheal allograft rejection. 2002 Transplant. Proc. pmid:12176430
Benedini S et al. Glucose and leucine metabolism in lung tranplanted patients on low dose of steroids for immunosuppressive therapy. 2008 Transplant. Proc. pmid:18589153
Tannuri AC et al. Effects of immunosuppressants on hepatocyte cell mitosis during liver regeneration in growing animal models of partial hepatectomy. 2008 Transplant. Proc. pmid:18589165
Tashiro H et al. Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. 1995 Transplant. Proc. pmid:7533421
Shirakata Y et al. The minimum graft size for successful orthotopic partial liver transplantation in the canine model. 1995 Transplant. Proc. pmid:7533422
Felser I et al. Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721350
Krämer BK et al. Cardiovascular risk estimates and risk factors in renal transplant recipients. 2005 Transplant. Proc. pmid:15919488
Alessiani M et al. CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721351
Moro JA et al. Randomized prospective study of the evolution of renal function depending on the anticalcineurin used. 2008 Transplant. Proc. pmid:19010143
Barrera-Pulido L et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. 2008 Transplant. Proc. pmid:19010156
Tanabe K et al. Outcome of kidney transplantation from non-heart-beating donors followed by tacrolimus immunosuppression in japan. 2002 Transplant. Proc. pmid:12176493
Gruttadauria S et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182762
Yoshimura N et al. Effect of local immunosuppressive therapy with FK 506 on renal allograft survival in the mongrel dog. 1998 Transplant. Proc. pmid:9838372
Wilusz M et al. Effects of Immunosuppressive Drugs on Serum Fatty Acids of Phospholipids Fraction in Renal Transplant Recipients. 2016 Transplant. Proc. pmid:27496457
Bonatti H et al. Liver transplantation for acute liver failure in children under 1 year of age. 1997 Feb-Mar Transplant. Proc. pmid:9123068
Cicalese L et al. Effect of FK506 on the mucosal perfusion of the rat intestinal allograft. 1996 Transplant. Proc. pmid:8907959
Oishi M et al. Successful swine small bowel transplantation using FK506: effect on endotoxin translocation. 1994 Transplant. Proc. pmid:7520629
Miki T et al. Xenogeneic humoral graft-Vs-host disease following hamster-to-Rat bone marrow transplantation. 2000 Transplant. Proc. pmid:10936339
Wada Y et al. Expression of the transcriptional factor egr-1/BTEB2 in cardiac xenograft vascular remodeling. 2000 Transplant. Proc. pmid:10936371
Moutabarrik A et al. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. 1991 Transplant. Proc. pmid:1721382
Moutabarrik A et al. In vitro FK 506 kidney tubular cell toxicity. 1991 Transplant. Proc. pmid:1721383
Moons P et al. Steroids may compromise quality of life of renal transplant recipients on a tacrolimus-based regimen. 2002 Transplant. Proc. pmid:12176538
Sharma A et al. Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression. 2008 Transplant. Proc. pmid:18790252
Beaunoyer M et al. Low-dose tacrolimus, trough-monitored mycophenolate mofetil, and planned steroid withdrawal for cadaveric kidney transplantation: a single center experience. 2002 Transplant. Proc. pmid:12176540
McAlister VC et al. Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. 1999 Feb-Mar Transplant. Proc. pmid:10083495
Gu B et al. Exploration of Fecal Microbiota Transplantation in the Treatment of Refractory Diarrhea After Renal Transplantation. 2018 Transplant. Proc. pmid:29880353
Basadonna GP et al. Pancreas after kidney transplantation: HLA mismatch does not preclude success. 1997 Feb-Mar Transplant. Proc. pmid:9123470
Alessiani M et al. Correlations between functional changes and different grades of acute rejection in swine small bowel allografts. 2000 Transplant. Proc. pmid:10995933
Yamashita T et al. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. 1991 Transplant. Proc. pmid:1721414
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Weir MR Optimizing early de novo immunosuppression with sirolimus. 2008 Transplant. Proc. pmid:19100903
Chang HR et al. Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity. 2004 Transplant. Proc. pmid:15621119
Khwaja K et al. Pancreas transplantation in cross-match-positive recipients using cyclosporine- or tacrolimus-based immunosuppression. 2002 Transplant. Proc. pmid:12176621
Beckebaum S et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. 2004 Transplant. Proc. pmid:15621120
Wang W et al. Effect of rapamycin and FK506 on mesangial cell proliferation. 2001 Feb-Mar Transplant. Proc. pmid:11267180
Rintala JM et al. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression. 2006 Transplant. Proc. pmid:17175234
Ishikawa S et al. Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney Transplantation: A Case Report. 2018 Transplant. Proc. pmid:29661455
Curtis JJ Posttransplant hypertension. 1998 Transplant. Proc. pmid:9723370
Yoshimura R et al. Hepatocyte growth factor: a sensitive indicator for CsA-induced nephropathy. 1998 Transplant. Proc. pmid:9723373
Lin CY et al. Effects of FK 506 on the biochemical markers in canine lung allograft rejection. 1991 Transplant. Proc. pmid:1721445
Propper DJ et al. Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. 1991 Transplant. Proc. pmid:1721446
Jost U et al. FK 506 treatment of intractable rejection after liver transplantation. 1993 Transplant. Proc. pmid:7689276
Winkler M et al. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. 1993 Transplant. Proc. pmid:7689277
Kiji T et al. Relationship between immunological rejection and matrix GLA protein in cryopreserved vascular allografts. 2004 Transplant. Proc. pmid:15561265
Heffron TG et al. Daclizumab induction in liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267408
Nakai T et al. Immunologic changes in heterotopic and orthotopic small bowel transplantation in rats. 1999 Transplant. Proc. pmid:10500761
Krüger B et al. Different effects of cyclosporine or tacrolimus on hepatocyte acute phase proteins. 1998 Transplant. Proc. pmid:9636399
Ben-Ari Z et al. Conversion of liver allograft recipients from cyclosporine A to FK 506 immunosuppressive therapy. 2000 Transplant. Proc. pmid:10856553
Barak S et al. Alveolar bone height in patients after liver transplantation. 2000 Transplant. Proc. pmid:10856558
Nanmoku K et al. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28923615
Girman P et al. Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. 2010 Jul-Aug Transplant. Proc. pmid:20692391
Keshavamurthy M et al. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral. 2001 Nov-Dec Transplant. Proc. pmid:11750338
Shapiro R The development of tacrolimus in renal transplantation. 2001 Nov-Dec Transplant. Proc. pmid:11750356
Fernando ON et al. Elective conversion of patients from cyclosporine to tacrolimus for hypertrichosis. 1998 Transplant. Proc. pmid:9636505
Morris-Stiff G et al. Conversion from cyclosporine to tacrolimus in renal allograft recipients with chronic graft nephropathy: preliminary report. 1998 Transplant. Proc. pmid:9636506